Tumor samples exhibited elevated levels of monophosphorylated pT-ERK1/2 in contrast to non-tumor samples, indicating a potential alteration in MEK-dependent ERK phosphorylation to prevent pathway hyperactivation [90]. The gene discussed is MAPK1; the disease is neoplasm.